Found 7 Lupus trials
A listing of Lupus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
XCI Maintenance in Scleroderma and Related Female-Biased Diseases
The research study is being done to understand both why and how scleroderma and related female-biased diseases affect women and men differently. Though we do not know what causes these diseases, we do know that women are much more likely to develop them than men. We are studying how the …
Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus. The study duration will be 48 weeks, with a safety follow-up through week 56.
A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants with Moderate-to-Severe Primary Discoid Lupus Erythematosus
PURPOSE: Phase 2 study to evaluate effect of daxdilimab vs placebo to reduce DLE activity in adults 18-75 yo with DLE. 60 wks 99 pts multiple sites 3 trx grps: placebo; daxdilimab 150 mg; daxdilimab 300 mg. Randomize 1:1:1 sc injections q 4 wks Screening--4 wks; Treatment--48 wks; Follow-Up--8 wks. …
Observational study of COVID-19 vaccine responses in patients with autoimmune diseases
Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, SLE, Sjogren’s Disease, Multiple Sclerosis, Scleroderma, Vasculitis or Blistering Diseases will undergo a blood draw and collection of clinical information prior to receipt of COVID-19 vaccination. Subjects will undergo a repeat blood draw and collection of clinical information at 4-10 weeks, 6 months …
Detection and Characterization of Subclinical Atherosclerotic Plaques in High-Risk Populations of Lupus Erythematosus and Dermatomyositis Patients: A Prospective Single-Center Cohort Study
To determine the burden of subclinical coronary and iliofemoral arterial plaque in 30- to 50-year-old patients with lupus erythematosus (LE) or dermatomyositis (DM) but no clinically evident atherosclerotic cardiovascular disease (ASCVD); and to determine the nature, location, and characteristics of subclinical plaques in these patients. To detect the extent and …
Test STudy67
-For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to 18 months or 10 to 50 years on the day of …
Evaluating Study Drug BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
The research study is being conducted to investigate if the study drug BIIB059 can reduce disease activity and inflammation in people with active Cutaneous Lupus Erythematosus compared to a placebo. Participants will complete the following research procedures: demography and medical history, previous CLE therapy, SARS-CoV-2 (COVID-19) test, chest X-ray, skin …
Please choose between Voice or SMS based delivery of verification code
or